Development of cell-penetrating bispecific antibodies targeting the N-terminal domain of androgen receptor for prostate cancer therapy.

about

Development of cell-penetrating bispecific antibodies targeting the N-terminal domain of androgen receptor for prostate cancer therapy.

Item

http://www.wikidata.org/entity/Q47307286

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Development of cell-penetratin ...... r for prostate cancer therapy.

@en

Development of cell-penetratin ...... r for prostate cancer therapy.

@nl

type

Item

label

Development of cell-penetratin ...... r for prostate cancer therapy.

@en

Development of cell-penetratin ...... r for prostate cancer therapy.

@nl

prefLabel

Development of cell-penetratin ...... r for prostate cancer therapy.

@en

Development of cell-penetratin ...... r for prostate cancer therapy.

@nl

P1476

Development of cell-penetratin ...... or for prostate cancer therapy

@en

P2093

Grace Chan

http://www.w3.org/2001/XMLSchema#string

Mary G Blanton

http://www.w3.org/2001/XMLSchema#string

Michael B Lilly

http://www.w3.org/2001/XMLSchema#string

Nancy L Goicochea

http://www.w3.org/2001/XMLSchema#string

Richard Weisbart

http://www.w3.org/2001/XMLSchema#string

P2860

Metastatic castration-resistant prostate cancer: new therapies, novel combination strategies and implications for immunotherapy

A novel androgen receptor splice variant is up-regulated during prostate cancer progression and promotes androgen depletion-resistant growth

A cancer specific cell-penetrating peptide, BR2, for the efficient delivery of an scFv into cancer cells

Characterization of niphatenones that inhibit androgen receptor N-terminal domain

Ligand binding to the androgen receptor induces conformational changes that regulate phosphatase interactions

Red Marrow-Absorbed Dose for Non-Hodgkin Lymphoma Patients Treated with 177Lu-Lilotomab Satetraxetan, a Novel Anti-CD37 Antibody-Radionuclide Conjugate.

Gene silencing by cell-penetrating, sequence-selective and nucleic-acid hydrolyzing antibodies

Small molecule inhibitors targeting the "achilles' heel" of androgen receptor activity

The roles of androgen receptors and androgen-binding proteins in nongenomic androgen actions.

EPI-001 is a selective peroxisome proliferator-activated receptor-gamma modulator with inhibitory effects on androgen receptor expression and activity in prostate cancer

P304

785-793

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/PROTEIN/GZX058

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Maria Garnovskaya

P577

2017-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29228299

http://www.w3.org/2001/XMLSchema#string